International Edition
Latest News
Health

FDA Grants RDEP Designation to NanoRetinal’s NAR-001 for RLBP1 Retinal Dystrophy

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research granted Rare Disease Evidence Principles designation to NanoRetinal Inc.’s investigational therapy NAR-001 for RLBP1-associated retinal dystrophy, the company announced Nov. 19. The designation applies to an…

FDA Grants RDEP Designation to NanoRetinal's NAR-001 for RLBP1 Retinal Dystrophy

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research granted Rare Disease Evidence Principles designation to NanoRetinal Inc.’s investigational therapy NAR-001 for RLBP1-associated retinal dystrophy, the company announced Nov. 19.

The designation applies to an intravitreal protein-based therapy designed to restore the visual cycle without genetic modification, according to the Princeton, N.J.-based biotechnology startup. NAR-001 targets a specific genetic defect for which no approved treatment exists.

“We are thrilled with the RDEP designation and our chance to help prevent blindness by treating patients with the RLBP-1 retinal disease,” said John Cullity, NanoRetinal’s CEO. “Our patented technology restores retinal visual pigment helping preserve vision for RP patients.”

FDA Grants RDEP Designation to NanoRetinal's NAR-001 for RLBP1 Retinal Dystrophy
Photo: manilatimes.net

The FDA introduced the RDEP framework in September 2025 to address regulatory challenges for ultra-rare, genetically defined diseases with significant unmet medical needs. Under the framework, substantial evidence of effectiveness may generally be established through one adequate and well-controlled study supported by strong confirmatory evidence of a treatment effect, the agency said.

NanoRetinal qualified for the pathway by targeting a specific genetic defect where no therapy currently exists, the company said. “The RDEP pathway is tailor-made for the NAR-001 program,” Cullity said.

RLBP1-associated retinal dystrophy is a form of retinitis pigmentosa caused by mutations that impair the structure and function of visual pigment, an essential element for vision. NAR-001 is engineered to increase the availability, photostability and durability of visual pigment, according to the company.

The investigational therapy uses an intravitreal protein-based approach intended to restore the visual cycle without genetic modification. NanoRetinal is developing nanoparticle-based treatments using technology licensed from the University of Bern in Switzerland.

NanoRetinal Inc. is a privately held biotechnology startup based at Princeton Innovation Center BioLabs in Princeton, New Jersey. The company is focused on developing nanoparticle-based therapies to restore and preserve vision in patients with inherited retinal diseases such as retinitis pigmentosa.

NanoRetinal is developing nanoparticle-based treatments using technology licensed from the University of Bern in Switzerland, a public research university founded in 1834 and financed by the canton of Bern.

With around 19,000 students, it is the third largest university in Switzerland and operates on the principle of a university in the city, with most institutes located in the Länggasse district near the centre. Albert Einstein taught theoretical physics there for three semesters starting in 1908, and in 1909 surgeon Theodor Kocher received the Nobel Prize in Medicine.

Media inquiries can be directed to Christie Markowitz at christie@markowitzstrategic.com or 617-610-9563. Investor and government relations contacts are Mike Smith at mike@msbdinc.com or 703-623-3834.

About the author: Health Desk

Health Desk at Archynewsy.